Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Profit After Tax (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Profit After Tax for 8 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax changed N/A to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$30.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$33.9 million for FY2025, 11.39% up from the prior year.
  • Profit After Tax for Q4 2025 was -$2.3 million at Actinium Pharmaceuticals, up from -$5.1 million in the prior quarter.
  • The five-year high for Profit After Tax was -$2.3 million in Q4 2025, with the low at -$15.9 million in Q1 2025.
  • Average Profit After Tax over 5 years is -$8.9 million, with a median of -$8.7 million recorded in 2024.
  • The sharpest move saw Profit After Tax crashed 115.19% in 2023, then skyrocketed 55.64% in 2025.
  • Over 5 years, Profit After Tax stood at -$8.0 million in 2021, then plummeted by 32.92% to -$10.6 million in 2022, then rose by 12.43% to -$9.3 million in 2023, then fell by 24.07% to -$11.6 million in 2024, then soared by 80.15% to -$2.3 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$2.3 million, -$5.1 million, and -$6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.